Our Board of Directors guides our business strategy and ensures that we practice good governance across our operations. As part of its normal course of business, the Board regularly participates in discussions on specific ESG issues core to our business strategy, including R&D initiatives, efforts to expand access to our medicines, and employee engagement activities.
Given the increasing importance of ESG to both our company and external stakeholders, the Board established a dedicated ESG Working Group in June 2022. The Working Group, comprising four Board members and seven employees from different functions, meets quarterly with BeiGene’s ESG team to review pressing ESG topics and keep apprised of emerging issues.
In addition, across the organization colleagues are constantly interacting and learning from various stakeholders that have a vested interest in how we manage our business and our ESG strategy. We leverage these insights from these interactions to inform our ESG goals and programs. We also participate in a number of industry associations and professional networks allowing us to exchange information on best practices for the betterment of the industry. We are proud to be a founding partner in the UICC ATOM Coalition and a member of the UN Global Compact.
Women continue to be underrepresented in leadership roles within the biotechnology sector. BeiGene has equal representation at levels below the VP level, but the percentage falls dramatically for women at the VP level and above. We need to remedy that. This fall, we became members of the UN Global Compact. We chose to accelerate progress on Gender Equality with the ambitious benchmark of achieving global gender parity in the VP level and above by 2030. We’re excited to roll out this plan along with our other DEI&B initiatives as we work to create a diverse and inclusive culture where everyone feels valued and a sense of belonging.
Linda Marchese, VP, Global Total Rewards & Diversity
Learn more about our commitment to Diversity, Equity, Inclusion and Belonging.
Our Code of Conduct guides our daily interactions with one another and with all of our stakeholders—from our patients and their doctors to government regulators and our collaboration partners. We pursue our business objectives with integrity and respect and in compliance with applicable laws and regulations. Our Code of Conduct addresses issues, including compliance, interactions with healthcare professionals, anti-competitive behavior, conflicts of interest, confidentiality, and more. We continually promote a culture of compliance and ethical operations through new hire and regular trainings and maintain robust monitoring and reporting systems. Each year, employees are asked to certify that they understand and will comply with our Code of Conduct, which covers our Anti-Bribery & Corruption and Harassment, Discrimination, & Anti-Retaliation policies.
BeiGene seeks to partner with suppliers who share our commitment to high-quality products and responsible operations as detailed in our Supplier Code of Conduct. All members of the procurement team receive corporate trainings on our procurement policies and approach.
In addition, to lower our environmental footprint and ensure the continuity of the supplies we need, BeiGene is increasingly prioritizing working with local suppliers, meaning suppliers within the country or region where the supplies or services are required.
BeiGene supports healthcare industry efforts and government policies that advance science, enhance medical innovation and ensure treatment affordability for patients around the world. We endeavor to earn the trust of our stakeholders by putting patients first, conducting business responsibly and being open and transparent. We disclose our interactions with stakeholders in accordance with relevant regional and national laws, regulations, and industry-specific codes. Learn more here.
Implement a Third-Party Supplier Risk Management program in 2023.